Prime Medicine reported revenue of $1.15M and net income of -$42.12M for the quarter ended Jun 2026, up 3.5% year over year. This income statement covers 20 quarters of results from Sep 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 14.97M | 12.97M | 19.05M | 20.23M | 22.23M | 33.89M | 97.23M | 97.27M | 97.32M | 97.38M | 120.02M | 120.03M | 131.16M | 131.16M | 131.16M | 134.49M | 180.31M | 148.76M | 180.62M | 180.74M |
| Revenue & cost | ||||||||||||||||||||
| Revenue | 0.59M | 0.21M | 2.18M | 1.45M | 1.11M | 1.23M | 0.84M | 0.86M | 1.15M | |||||||||||
| Operating items | ||||||||||||||||||||
| Research & DevelopmentR&D | 7.40M | 52.89M | 13.68M | 18.94M | 25.05M | 29.06M | 30.88M | 34.60M | 40.97M | 41.46M | 37.77M | 43.07M | 40.34M | 34.10M | 40.56M | 41.38M | 43.99M | 34.71M | 34.10M | 33.40M |
| Selling, General & AdministrativeSG&A | 3.03M | 7.19M | 6.22M | 7.37M | 6.61M | 9.62M | 9.15M | 10.66M | 10.49M | 13.08M | 11.16M | 12.60M | 14.10M | 12.30M | 13.28M | 13.12M | 11.21M | 14.74M | 17.41M | 11.04M |
| Other Operating ExpensesOther Opex | 13.50M | |||||||||||||||||||
| Operating ExpensesOpex | 10.43M | 60.08M | 19.90M | 26.30M | 31.66M | 38.69M | 40.03M | 45.26M | 51.46M | 68.04M | 48.93M | 55.67M | 54.44M | 46.41M | 53.85M | 54.49M | 55.20M | 49.45M | 51.51M | 44.44M |
| Operating IncomeOp. Inc | -10.43M | -60.08M | -19.90M | -26.30M | -31.66M | -38.69M | -40.03M | -45.26M | -51.46M | -68.04M | -48.34M | -55.67M | -54.23M | -44.22M | -52.39M | -53.38M | -53.97M | -48.61M | -50.65M | -43.28M |
| EBIT | -10.43M | -60.08M | -19.90M | -26.30M | -31.66M | -38.69M | -40.03M | -45.26M | -51.46M | -68.04M | -48.34M | -55.67M | -54.23M | -44.22M | -52.39M | -53.38M | -53.97M | -48.61M | -50.65M | -43.28M |
| Non-operating items | ||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.64M | 0.41M | 0.49M | 0.68M | 0.61M | 0.70M | 1.54M | 1.18M | 0.74M | 1.14M | 1.08M | 1.02M | 0.79M | |||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.00M | 0.01M | 0.01M | 0.24M | 0.73M | 0.93M | 2.13M | 0.04M | 0.04M | 0.15M | 0.04M | 0.04M | -0.08M | 0.04M | 0.04M | 0.02M | 0.04M | 0.05M | 0.05M | 0.06M |
| Non Operating IncomeNon Op. Inc. | -8.36M | -1.45M | -4.47M | -3.48M | 2.52M | -0.78M | 0.43M | 2.90M | 0.64M | 2.40M | 2.71M | 0.21M | 1.71M | 1.95M | 0.50M | 0.79M | 3.39M | 2.53M | 1.53M | 1.18M |
| Net income details | ||||||||||||||||||||
| EBT | -18.78M | -61.53M | -24.37M | -29.79M | -29.14M | -39.47M | -39.60M | -42.35M | -50.82M | -65.64M | -45.63M | -55.46M | -52.52M | -42.28M | -51.89M | -52.59M | -52.83M | -47.52M | -49.63M | -42.50M |
| Tax ProvisionsTaxes | -2.37M | 1.37M | -0.53M | -0.44M | 0.21M | -0.19M | -0.20M | 0.03M | -0.11M | 0.13M | -0.13M | |||||||||
| Profit After TaxPAT | -22.77M | -69.27M | -23.84M | -29.35M | -35.71M | -40.60M | -39.40M | -42.38M | -50.71M | -65.64M | -45.76M | -55.33M | -52.52M | -42.28M | -51.89M | -52.59M | -50.58M | -46.08M | -49.12M | -42.12M |
| Income from Continuing OperationsIncome (Continuing) | -16.41M | -62.90M | -23.84M | -29.35M | -29.35M | -39.28M | -39.40M | -42.38M | -50.71M | -65.64M | -45.76M | -55.33M | -52.52M | -42.28M | -51.89M | -52.59M | -52.83M | -47.52M | -49.63M | -42.50M |
| Consolidated Net IncomeConsol Net Inc. | -16.41M | -62.90M | -23.84M | -29.35M | -29.35M | -39.28M | -39.40M | -42.38M | -50.71M | -65.64M | -45.76M | -55.33M | -52.52M | -42.28M | -51.89M | -52.59M | -52.83M | -47.52M | -49.63M | -42.50M |
| Income towards Parent CompanyParent Net Inc | -16.41M | -62.90M | -23.84M | -29.35M | -29.35M | -39.28M | -39.40M | -42.38M | -50.71M | -65.64M | -45.76M | -55.33M | -52.52M | -42.28M | -51.89M | -52.59M | -52.83M | -47.52M | -49.63M | -42.50M |
| Preferred Dividend PaymentsPref Dividends | 6.36M | 6.36M | 6.22M | 6.29M | 6.36M | 1.31M | ||||||||||||||
| Net Income towards Common StockholdersNet Income | -22.77M | -69.27M | -30.06M | -35.64M | -35.71M | -40.60M | -39.40M | -42.38M | -50.71M | -65.64M | -45.76M | -55.33M | -52.52M | -42.28M | -51.89M | -52.59M | -50.58M | -46.08M | -49.12M | -42.11M |
| Additional items | ||||||||||||||||||||
| EPS (Basic) | -1.52 | -5.34 | -1.58 | -1.76 | -1.61 | -1.20 | -0.44 | -0.47 | -0.55 | -0.72 | -0.44 | -0.46 | -0.44 | -0.36 | -0.40 | -0.41 | -0.32 | -0.31 | -0.28 | -0.24 |
| EPS (Diluted) | -1.52 | -5.34 | -1.58 | -1.76 | -1.61 | -1.20 | -0.44 | -0.47 | -0.55 | -0.72 | -0.44 | -0.46 | -0.44 | -0.36 | -0.40 | -0.41 | -0.32 | -0.31 | -0.28 | -0.24 |
| Shares Outstanding | 14.97M | 12.97M | 19.05M | 20.23M | 22.23M | 33.89M | 89.06M | 90.47M | 91.85M | 90.97M | 104.47M | 119.19M | 119.76M | 118.60M | 130.88M | 129.19M | 160.50M | 148.76M | 177.10M | 177.22M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 14.97M | 12.97M | 19.05M | 20.23M | 22.23M | 33.89M | 89.06M | 90.47M | 91.85M | 90.97M | 104.47M | 119.19M | 119.76M | 118.60M | 130.88M | 129.19M | 160.50M | 148.76M | 177.10M | 177.22M |
| EBITDA | -10.43M | -60.08M | -19.90M | -26.30M | -31.66M | -38.69M | -40.03M | -45.26M | -51.46M | -68.04M | -48.34M | -55.67M | -54.23M | -44.22M | -52.39M | -53.38M | -53.97M | -48.61M | -50.65M | -43.28M |
| Tax Rate | 12.62 | -2.22 | 2.18 | 1.48 | -0.73 | 0.47 | 0.51 | -0.07 | 0.21 | -0.29 | 0.24 |